RaySearch Laboratories AB (publ)
STO:RAY B
Intrinsic Value
RaySearch Laboratories AB is a medical technology company, which engages in the development of software solutions for improved radiation therapy of cancer. [ Read More ]
The intrinsic value of one
RAY B
stock under the Base Case scenario is
172.35
SEK.
Compared to the current market price of 133.6 SEK,
RaySearch Laboratories AB (publ)
is
Undervalued by 22%.
RaySearch Laboratories AB (publ)'s market capitalization is 4.6B SEK.
RAY B stock price is 133.6 SEK.
RAY B stock price (133.6 SEK) is 22% less than its Intrinsic Value (172.35 SEK).
RAY B stock price (133.6 SEK) is 35% less than its Relative Value (205.15 SEK). Open Relative Valuation
RAY B has upside potential of 1% compared to the average analyst price target.
Open Wall St Estimates
RAY B's ROE (Return on Equity) for the past 12 months is positive and is equal to 12%.
RAY B's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 5%.
RAY B's short-term assets (823m SEK) exceed its short-term liabilties (675m SEK).
RAY B has positive Net Debt. This means that the company has more debt (432m SEK) than cash and short-term investments (344m SEK).
RAY B's Revenue has grown by an exceptional 21% over the past 12 months.
RAY B's Revenue is forecast to grow at a rate of 12% per year over the next 3 years.
RAY B's ROIC (Return on Invested Capital) has increased in the last 3 years from -3% to 5%.
RAY B's Revenue has been growing by 16% per year for the last 3 years.
RAY B's long-term assets (2B SEK) exceed its long-term liabilties (1B SEK).
RAY B's Altman Z-Score is equal to 2.12.
RAY B has positive Operating Income for the last twelve months.
RAY B has positive Net Income for the last twelve months.
RAY B's ROE (Return on Equity) has significantly increased in the last 3 years from -6% to 12%.
RAY B has negative three-year average ROIC (Return on Invested Capital): 0%. The company is not efficient at using invested capital to generate operating income.
RAY B has negative three-year average ROE (Return on Equity): 0%. The company is not efficient at transforming stockholders' equity into net income.
RAY B's D/E (Debt to Equity) is very low and is equal to 0.59.
RAY B has positive Gross Profit for the last twelve months.
RAY B has positive Free Cash Flow for the last twelve months.
Valuation Backtest
RaySearch Laboratories AB (publ)
Run backtest to discover the historical profit from buying and selling
RAY B
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
RaySearch Laboratories AB (publ)
Balance Sheet Decomposition
RaySearch Laboratories AB (publ)
| Current Assets | 823.4m |
| Cash & Short-Term Investments | 343.7m |
| Receivables | 470.4m |
| Other Current Assets | 9.3m |
| Non-Current Assets | 1.1B |
| PP&E | 590.4m |
| Intangibles | 530.5m |
| Other Non-Current Assets | 8.4m |
| Current Liabilities | 675m |
| Accounts Payable | 42.1m |
| Other Current Liabilities | 633m |
| Non-Current Liabilities | 542.4m |
| Long-Term Debt | 432m |
| Other Non-Current Liabilities | 110.4m |
Earnings Waterfall
RaySearch Laboratories AB (publ)
|
Revenue
|
1B
SEK
|
|
Cost of Revenue
|
-106.6m
SEK
|
|
Gross Profit
|
915.6m
SEK
|
|
Operating Expenses
|
-800.7m
SEK
|
|
Operating Income
|
114.9m
SEK
|
|
Other Expenses
|
-33.3m
SEK
|
|
Net Income
|
81.6m
SEK
|
Free Cash Flow Analysis
RaySearch Laboratories AB (publ)
RAY B Profitability Score
Profitability Due Diligence
RaySearch Laboratories AB (publ)'s profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
RaySearch Laboratories AB (publ)'s profitability score is 55/100. The higher the profitability score, the more profitable the company is.
RAY B Solvency Score
Solvency Due Diligence
RaySearch Laboratories AB (publ)'s solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
RaySearch Laboratories AB (publ)'s solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RAY B Price Targets Summary
RaySearch Laboratories AB (publ)
According to Wall Street analysts, the average 1-year price target for
RAY B
is 135 SEK
.
Shareholder Return
RAY B Price
RaySearch Laboratories AB (publ)
| Average Annual Return | -11.98% |
| Standard Deviation of Annual Returns | 25.21% |
| Max Drawdown | -78% |
| Market Capitalization | 4.6B SEK |
| Shares Outstanding | 34 282 773 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
RaySearch Laboratories AB (publ)
Country
Industry
Market Cap
Dividend Yield
Description
RaySearch Laboratories AB is a medical technology company, which engages in the development of software solutions for improved radiation therapy of cancer. The company is headquartered in Stockholm, Stockholm. The company markets and sells its products mainly in the United States and in Europe through license agreements with medical technology companies and scientific institutions. As of December 31, 2011, 15 of the Company’s products were launched, including the software platform ORBIT (optimization of radiation therapy beams by iterative technique), which is available in its main products, and is a non-clinical system which functions as a research and development environment. Additionally, its solutions include software for optimizing Intensity Modulated Radiation Therapy (IMRT) plans for photons, adaptive technology for IMRT treatments and software for proton treatments. The Company’s commercial partners are Philips, Nucletron and IBA Dosimetry, among others. In April 2014, it established a German subsidiary, RaySearch Germany GmbH.
Contact
IPO
Employees
Officers
The intrinsic value of one
RAY B
stock under the Base Case scenario is
172.35
SEK.
Compared to the current market price of 133.6 SEK,
RaySearch Laboratories AB (publ)
is
Undervalued by 22%.
You don't have any saved screeners yet
